Cell Biochemistry and Biophysics, Год журнала: 2025, Номер unknown
Опубликована: Апрель 17, 2025
Язык: Английский
Cell Biochemistry and Biophysics, Год журнала: 2025, Номер unknown
Опубликована: Апрель 17, 2025
Язык: Английский
Trends in Cardiovascular Medicine, Год журнала: 2025, Номер 35(4), С. 258 - 265
Опубликована: Янв. 21, 2025
Язык: Английский
Процитировано
5Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 160271 - 160271
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0BMC Gastroenterology, Год журнала: 2025, Номер 25(1)
Опубликована: Март 7, 2025
With the rising incidence of MASLD, extensive drug research has been conducted in clinical trials. The study examined design principles and objectives MASLD therapeutics, order to offer guidance trial participants decision makers. By searching data registered on clinicaltrials.gov platform, 1209 interventional trials were screened. These subsequently evaluated based stage, design, intervention modalities, outcome metrics, other pertinent factors. A total 1,209 included, which 199 from 2000 2012 (16.46%) 1010 2013 2024 (83.54%), reflecting growing body MASLD. Regarding model type, single-group designs employed 232 (19.19%) trials, parallel 873(72.21%). 13 early phase 1 (1.08%), 152 (12.57%) 1, 34 (2.81%) 1/phase 2, 301 2 (24.90%), 19 (1.57%) 2/phase 3, 72 (5.96%) 84 (6.95%) 4. Within these three primary outcomes for interventions hepatic histological improvement, fat content adverse events. Furthermore, 140 with results therapeutic purposes (This accounted 88.61% 158 results) primarily aimed improve through mechanisms such as metabolic energy balance, inflammatory immunomodulatory, lipid reduction, targeting PPAR, FXR, ACC GLP-1. This suggests basic characteristics global current are mainly focused drug-related treatments, drugs inflammation metabolism still first choice studies.
Язык: Английский
Процитировано
0BMC Neurology, Год журнала: 2025, Номер 25(1)
Опубликована: Апрель 16, 2025
This study aims to investigate the causal relationship between Mitochondrial DNA (mtDNA) copy number and several common neurodegenerative diseases (NDs). We conducted a bidirectional two-sample Mendelian randomization (MR) analysis using data from genome-wide association studies (GWAS) as instrumental variables (IVs). After screening for relevance potential confounders, we estimated mtDNA NDs, including Alzheimer's disease (AD), Parkinson's (PD), Amyotrophic lateral sclerosis (ALS), Multiple (MS). Additionally, validated our findings GWAS on Longchamps et al., sourced Genetics Epidemiology Consortium UK Biobank (UKB) aging cohort. A of 395,718 UKB participants found no significant risk AD (OR = 0.956, P 0.708), PD 1.223, 0.179), ALS 0.972, 0.374), MS 0.932, 0.789). Similarly, reverse MR revealed genetic predictions NDs number: 0.987, 0.062), 0.997, 0.514), 0.974, 0.706), 1.003, 0.181). Although mitochondrial dysfunction is implicated in pathogenesis clear evidence supports role number. The likely mediated by more complex molecular regulatory mechanisms. Further research required elucidate these intricate interactions.
Язык: Английский
Процитировано
0Cell Biochemistry and Biophysics, Год журнала: 2025, Номер unknown
Опубликована: Апрель 17, 2025
Язык: Английский
Процитировано
0